BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26907177)

  • 1. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
    Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
    J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Processing of mutant N-acetyl-α-glucosaminidase in mucopolysaccharidosis type IIIB fibroblasts cultured at low temperature.
    Meijer OLM; Te Brinke H; Ofman R; IJlst L; Wijburg FA; van Vlies N
    Mol Genet Metab; 2017 Sep; 122(1-2):100-106. PubMed ID: 28751108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.
    Ellinwood NM; Wang P; Skeen T; Sharp NJ; Cesta M; Decker S; Edwards NJ; Bublot I; Thompson JN; Bush W; Hardam E; Haskins ME; Giger U
    J Inherit Metab Dis; 2003; 26(5):489-504. PubMed ID: 14518829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
    Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
    Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput Screen Fails to Identify Compounds That Enhance Residual Enzyme Activity of Mutant N-Acetyl-α-Glucosaminidase in Mucopolysaccharidosis Type IIIB.
    Meijer OLM; van den Biggelaar P; Ofman R; Wijburg FA; van Vlies N
    JIMD Rep; 2018; 39():97-106. PubMed ID: 28836185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
    Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
    Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
    Mohammed EE; Snella EM; Rutz-Mendicino MM; Echevarria FD; Awedikian R; Whitley EM; Ellinwood NM
    Mol Genet Metab; 2012 Sep; 107(1-2):129-35. PubMed ID: 22867887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)].
    Zhang WM; Shi HP; Meng Y; Li BT; Qiu ZQ; Liu JT
    Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):407-10. PubMed ID: 19099774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
    Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
    PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
    Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
    Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene.
    Huang W; Xu M; Li R; Baskfield A; Kouznetsova J; Beers J; Zou J; Liu C; Zheng W
    Stem Cell Res; 2019 May; 37():101427. PubMed ID: 30933722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine cellular model of mucopolysaccharidosis, type IIIB (MPS IIIB) - A preliminary study with particular emphasis on the non-oxidative l-cysteine metabolism.
    Kaczor-Kamińska M; Stalińska K; Kamiński K; Pisarek A; Maziarz U; Feldman A; Wróbel M
    Biochimie; 2020 Jul; 174():84-94. PubMed ID: 32335228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untypically mild phenotype of a patient suffering from Sanfilippo syndrome B with the c.638C>T/c.889C>T (p.Pro213Leu/p.Arg297Ter) mutations in the NAGLU gene.
    Pierzynowska K; Mański A; Limanówka M; Wierzba J; Gaffke L; Anikiej P; Węgrzyn G
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1356. PubMed ID: 32578945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis IIIB and mild skeletal anomalies: coexistence of NAGLU and CYP26B1 missense variations in the same patient in a Chinese family.
    Li J; Xie H; Jiang Y
    BMC Med Genet; 2018 Apr; 19(1):51. PubMed ID: 29606097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
    Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM
    Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient.
    Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D
    Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.
    Schiattarella GG; Cerulo G; De Pasquale V; Cocchiaro P; Paciello O; Avallone L; Belfiore MP; Iacobellis F; Di Napoli D; Magliulo F; Perrino C; Trimarco B; Esposito G; Di Natale P; Pavone LM
    PLoS One; 2015; 10(7):e0131662. PubMed ID: 26147524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.